1. Home
  2. CELC vs NN Comparison

CELC vs NN Comparison

Compare CELC & NN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CELC
  • NN
  • Stock Information
  • Founded
  • CELC 2011
  • NN 2007
  • Country
  • CELC United States
  • NN United States
  • Employees
  • CELC N/A
  • NN N/A
  • Industry
  • CELC Medical Specialities
  • NN Industrial Machinery/Components
  • Sector
  • CELC Health Care
  • NN Industrials
  • Exchange
  • CELC Nasdaq
  • NN Nasdaq
  • Market Cap
  • CELC 2.3B
  • NN 1.9B
  • IPO Year
  • CELC 2017
  • NN N/A
  • Fundamental
  • Price
  • CELC $51.88
  • NN $12.52
  • Analyst Decision
  • CELC Strong Buy
  • NN
  • Analyst Count
  • CELC 5
  • NN 0
  • Target Price
  • CELC $67.20
  • NN N/A
  • AVG Volume (30 Days)
  • CELC 1.1M
  • NN 1.3M
  • Earning Date
  • CELC 11-13-2025
  • NN 11-12-2025
  • Dividend Yield
  • CELC N/A
  • NN N/A
  • EPS Growth
  • CELC N/A
  • NN N/A
  • EPS
  • CELC N/A
  • NN N/A
  • Revenue
  • CELC N/A
  • NN $6,259,000.00
  • Revenue This Year
  • CELC N/A
  • NN N/A
  • Revenue Next Year
  • CELC N/A
  • NN N/A
  • P/E Ratio
  • CELC N/A
  • NN N/A
  • Revenue Growth
  • CELC N/A
  • NN 42.80
  • 52 Week Low
  • CELC $7.58
  • NN $7.93
  • 52 Week High
  • CELC $63.06
  • NN $18.54
  • Technical
  • Relative Strength Index (RSI)
  • CELC 53.91
  • NN 24.02
  • Support Level
  • CELC $45.15
  • NN $12.86
  • Resistance Level
  • CELC $50.00
  • NN $13.98
  • Average True Range (ATR)
  • CELC 3.48
  • NN 0.68
  • MACD
  • CELC -0.04
  • NN -0.21
  • Stochastic Oscillator
  • CELC 64.67
  • NN 4.43

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

About NN NextNav Inc.

NextNav Inc provides GPS service. The company NextNav TerraPoiNT system keeps critical infrastructure resilient with reliable Position, Navigation, and Timing services in the absence of GPS.

Share on Social Networks: